HUTCHMED to Showcase Positive Savolitinib Phase II Results and Broad Fruquintinib/Surufatinib Analyses at 2026 ASCO

HUTCHMED (China) Limited announced that new and updated findings from its internally discovered oncology pipeline will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from 29 May to 2 June 2026.

The headline presentation features data from a pivotal Phase II registration study of savolitinib in Chinese patients with MET-amplified gastric cancer or gastroesophageal junction adenocarcinoma. As of the 8 October 2025 data cut-off, the Independent Review Committee assessed: • Objective response rate at 32.30% (95% CI: 21.20%, 45.10%), surpassing the pre-specified efficacy threshold. • Disease control rate of 63.10%. • Median time to response of 1.40 months. • Median duration of response of 9.70 months (95% CI: 3.70, 18.50). • Median progression-free survival of 4.00 months (95% CI: 2.60, 5.00).

These results supported the New Drug Application already accepted and granted priority review by China’s National Medical Products Administration in December 2025.

Beyond savolitinib, HUTCHMED will present additional analyses across its VEGFR inhibitors: • Fruquintinib: Depth-of-response data from FRESCO and FRESCO-2 in metastatic colorectal cancer, subgroup explorations in renal cell carcinoma (FRUSICA-2), and multiple investigator-initiated trials evaluating combinations with chemotherapy and immunotherapy in colorectal, gastric, esophageal and ovarian cancers. • Surufatinib: Updated combination data in intrahepatic cholangiocarcinoma, pancreatic ductal adenocarcinoma, ovarian clear cell carcinoma, thymic epithelial tumors and hepatocellular carcinoma.

The savolitinib study will be delivered in a Rapid Oral Session on 1 June, while fruquintinib and surufatinib findings will be detailed in poster, publication-only and late-breaking abstract formats across gastrointestinal, genitourinary, gynecologic and thoracic oncology tracks.

HUTCHMED positions these presentations as evidence of continued clinical progress for its three marketed assets—savolitinib, fruquintinib and surufatinib—and as support for global expansion strategies in targeted and immuno-oncology therapeutics.